VantroMarket Overview
← All markets
Health Market Overview

Netherlands

Last updated: November 2026
Regulatory Body
College ter Beoordeling van Geneesmiddelen (Medicines Evaluation Board, CBG-MEB) and Inspectie Gezondheidszorg en Jeugd (Health and Youth Care Inspectorate, IGJ)
Typical Timeline
60-210 days (national procedures); 210 days for centralised EMA procedures with ongoing national implementation steps
Regulatory Overview

The Netherlands operates within the European Union regulatory framework, meaning most health products are governed by EU-level legislation including Regulation (EU) 2017/745 for medical devices, Regulation (EU) 2017/746 for in vitro diagnostics, Directive 2001/83/EC and Regulation (EC) 536/2014 for pharmaceuticals, and the evolving EU Digital Health Strategy for digital health solutions. The primary national authority is the CBG-MEB, which handles national and mutual recognition pharmaceutical procedures, while the IGJ oversees market surveillance, post-market compliance, and enforcement for all health product categories. Pharmaceuticals may be approved via the centralised procedure (EMA), the mutual recognition procedure (MRP), the decentralised procedure (DCP), or a purely national procedure for locally specific products. Medical devices and IVDs require CE marking under Notified Body assessment, with Dutch-based Notified Bodies such as BSI Netherlands and DEKRA playing an active role.

For pharmaceutical submissions, the Common Technical Document (CTD) format is mandatory and aligned with ICH guidelines. A local EU-based qualified person for pharmacovigilance (QPPV) and an EU marketing authorisation holder or representative are required for all non-EU applicants. The Netherlands has been an active adopter of the EU Joint Clinical Assessment (EHTA Regulation (EU) 2021/2282), which harmonises HTA evaluations across member states and is being phased in from 2025 onward for oncology and ATMPs, with broader application by 2030. Recent reforms include full enforcement of MDR and IVDR timelines, strengthened post-market surveillance obligations, and the national implementation of the European Health Data Space (EHDS) initiative, which has significant implications for digital health and real-world evidence generation.

Procurement Overview

Public procurement of health products in the Netherlands is primarily coordinated through the Ministry of Health, Welfare and Sport (Ministerie van Volksgezondheid, Welzijn en Sport, VWS), with execution channeled through a combination of national frameworks and regional purchasing bodies. The national health insurance system is administered under the Health Insurance Act (Zorgverzekeringswet, Zvw), and reimbursement decisions are heavily influenced by assessments from the National Health Care Institute (Zorginstituut Nederland, ZIN), which conducts health technology assessments and advises on inclusion in the basic benefits package (Basisverzekeringspakket). Hospital procurement is largely decentralised, with individual hospital groups and procurement cooperatives such as Intrakoop negotiating directly with suppliers. Tender procedures must comply with EU public procurement directives (2014/24/EU), and contracts above threshold values are subject to open European tender processes published via TenderNed, the national e-procurement platform.

The private sector plays a meaningful role, with private insurers, pharmacy chains, and independent clinics procuring products outside the public reimbursement pathway, particularly for consumer health, diagnostics, and digital health applications. The Netherlands is a high-income country and does not typically receive donor-funded procurement support from bodies such as UNICEF, the Global Fund, USAID, or Gavi; however, Dutch institutions are active participants in international donor and global health procurement initiatives on the supply and financing side. There are no formal local manufacturing preference policies mandated in procurement law, though sustainability and supply chain resilience considerations have gained prominence post-COVID-19, and the European Health Emergency Preparedness and Response Authority (HERA) framework encourages strategic stockpiling and regional production capacity within the EU.

Go deeper

This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.

Generate a free Market Brief for Netherlands →
Market overview generated by AI and updated monthly. Verify with in-country regulatory authorities before making market entry decisions.